What question did this study set out to answer?

To assess the effectiveness of belzutifan in treating sporadic CNS hemangioblastomas.

June 13, 2026Neurology

Belzutifan Beyond VHL; Case Series of Sporadic Hemangioblastomas and the Expanding Role of HIF-inhibitors (P8-6.009)

View Full Paper

Ask AI

Bookmark

To assess the effectiveness of belzutifan in treating sporadic CNS hemangioblastomas.
Retrospective evaluation of clinical and radiographic responses.
Off-label use of belzutifan therapy in treated patients.
Focus on sporadic hemangioblastomas not linked to VHL.
Patients showed varied clinical responses to belzutifan therapy.
Radiographic improvements observed in some cases, indicating potential efficacy.
Further studies are needed to establish definitive outcomes.

Implication

Retrospective evaluation of belzutifan's clinical efficacy in sporadic CNS hemangioblastomas, suggesting potential applications beyond VHL.

Abstract

To retrospectively evaluate the clinical and radiographic response to off-label belzutifan therapy in patients with sporadic central nervous system (CNS) hemangioblastomas not associated with von Hippel-Lindau disease (VHL).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gunawardena et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f056591 https://doi.org/10.1212/wnl.0000000000213219

View Full Paper

Ask AI

Bookmark

Implication

Retrospective evaluation of belzutifan's clinical efficacy in sporadic CNS hemangioblastomas, suggesting potential applications beyond VHL.

Belzutifan Beyond VHL; Case Series of Sporadic Hemangioblastomas and the Expanding Role of HIF-inhibitors (P8-6.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Belzutifan Beyond VHL; Case Series of Sporadic Hemangioblastomas and the Expanding Role of HIF-inhibitors (P8-6.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading